Identification of **TLN1** as a prognostic biomarker to effect cell proliferation and differentiation in acute myeloid leukemia

Di Cui1†, Xilong Cui2†, Xiaoliang Xu3†, Wenjing Zhang4, Yu Yu2, Yingxin Gao3, Chuanzhong Mei3* and Weiwei Zheng4*

**Abstract**

The protein Talin1 encoded by the **TLN1** gene is a focal adhesion-related protein that binds to various cytoskeletal proteins and plays an important role in cell adhesion and movement. Recent studies have shown that it is overexpressed in prostate cancer, liver cancer, and oral squamous cell carcinoma, and is closely related to tumor progression and metastasis. This study integrated bioinformatics and functional analysis to reveal the prognosis and potential functions of **TLN1** in AML. The results showed that the expression level of **TLN1** was abnormally increased in AML and localized in the cell membrane and cytoplasm, and **TLN1** is a significant prognostic indicator of overall survival (OS). Enrichment analysis of related genes showed that **TLN1** is related to neutrophil mediated immunity, neutrophil activation and may regulate important signal pathways in hematological tumors including tyrosine kinase receptor, FLT3 and PIK3/AKT. The PPI network shows that **TLN1** and **MYH9** may be involved in the process of AML tumors together with **PPIP5K1C, ROCK1, S100A4, MY01A** and **WAC**. Immune infiltration analysis explains that **TLN1** is associated with multiple immune cells and may be an important immune marker in AML. Furthermore, molecular biology experiments confirmed that **TLN1** is related to the proliferation, differentiation and cycle of AML cells. Silencing **TLN1** can inhibit the proliferation of AML cells and promote differentiation through the Talin1/P-AKT/CREB signaling pathway.

**Keywords:** **TLN1**, Talin1, Acute myeloid leukemia, Prognostic, **MYH9**

**Introduction**

Acute myeloid leukemia (AML) is an aggressive hematological tumor characterized by the abnormal proliferation and differentiation of immature myeloid cells with a poor prognosis and is prone to drug resistance and recurrence [1]. According to cancer statistics 2020, 19,940 new cases and 11,180 deaths are expected to arise in America in 2020 [2]. Although the development and application of new drugs have greatly extended the median survival time of patients, most patients still experience recurrence, refractory or even death, and the overall survival rate is not satisfactory. A total of 57.4% of patients experience recurrence with genetic alterations that are difficult to treat [3]. The prognosis is even worse for these patients, only approximately 10% of patients surviving long term, with a median survival of 5 to 10 months [4]. Therefore, there is an urgent need to find new treatment targets and treatment plans in clinical practice to improve the remission rate and survival rate of patients and reduce adverse reactions after chemotherapy.
Integrin family adhesion molecules are the most important molecules that mediate the interaction between cells and the extracellular matrix. They recognize and bind the corresponding ligands in the extracellular matrix to provide attachment points for cell attachment. At the same time, it transmits signals from the extracellular environment to the cell, and regulates gene expression by activating multiple signal pathways, thereby regulating cell movement, proliferation and apoptosis [5]. Talin1 is a cytoskeletal protein with a weight of about 270kDa encoded by TLN1, which is the first adaptor protein to be confirmed to bind to integrin. It’s binding to the intracellular segment of the integrin subunit is the key link for integrin activation [6]. Talin1 contains 18 domains that bind at least 11 different fatty acid components, including vinculin and actin [7]. Recent studies have shown that the overexpression of TLN1 in oral squamous cell carcinoma, liver cancer, and prostate cancer is related to tumor invasion, metastasis, or poor differentiation. Molecular biology experiments have confirmed that it does promote the growth and invasion of tumor cells. Furthermore, the overexpression of TLN1 can significantly enhance the drug resistance of triple-negative breast cancer [8]. However, the role and mechanism of TLN1 in leukemia is still unclear. This study uses bioinformatics methods and molecular biology experiments to explore the functional role of TLN1 in the occurrence and development of AML.

Materials and methods

Data collection

The datas of RNA expression data, DNA methylation and transcript were downloaded from UCSC XENA (https://xenabrowser.net/datapages/), the RNAseq data in TPM format TCGA and GTEX processed uniformly by the Toil process [9], including AML patients of TCGA and normal controls of GTEX.

Molecular correlation analysis

To explore the related genes of TLN1 in AML, we used the LinkedOmics database (http://www.linkedomics.org/) to draw a volcano map, heat map, Pearson correlation coefficient or scatter plot.

GO|KEGG and gene set enrichment analysis (GSEA) enrichment analysis

Genes associated with TLN1 with the threshold for |pearson correlation coefficient| > 0.5 and p < 0.01 were applied for GO|KEGG enrichment analysis and GSEA enrichment analysis [10]. Use org.Hs.eg.db package version 3.10.0 for gene ID conversion and clusterProfiler package [11] version 3.14.3 for enrichment analysis in R. The GSEA enrichment analysis data set uses C2.all.v7.0.symbols.gmt.

Pathway activity and drug sensitivity

Use the Gene Set Cancer Analysis (GSCA) database to predict cancer pathway activity and drug sensitivity related to TLN1.

Protein-protein interaction (PPI) network and immune infiltration analysis

Used GeneMANIA to construct a PPI network and predict the part function of TLN1 [12]. Used version 1.34.0 of GSVA package to perform immune infiltration of TLN1 in AML. The correlation analysis method uses Spearman.

Cell culture

The human AML cell lines KG-1, MOLM13, Kasumin-1, K562, THP-1 and HL60 were provided by the Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China. AML cells were cultured with RPMI-1640 containing 10% fetal bovine serum at 37 °C and 5%CO2 saturated humidity.

Patient sample source

Human primary bone marrow cells were obtained from the First Affiliated Hospital of the University of Science and Technology of China. After obtaining the consent of the admitted AML patient, 3-5 ml of bone marrow or peripheral blood was collected. After mononuclear cells were extracted by density gradient centrifugation, the protein was extracted for subsequent experiments. Human primary cells were obtained after obtaining informed consent from AML patients according to the Declaration of Helsinki. This study was approved by the Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China.

Immunofluorescence staining and Wright–Giemsa staining

Collect the cells growing in the logarithmic phase, wash with PBS and smear. After fixation with 4% paraformaldehyde for 15 minutes, use goat serum to block overnight at 4 °C. After the primary antibody was incubated for 6 h, washed with PBST three times at 4 °C, and incubated with the secondary antibody (Dy light594) for 1 hour at room temperature. The slides were sealed with DAPI-containing anti-fluorescence quenching sealing tablets and observed under Zeiss LSM780 confocal microscope to collect images. Cell-smear was performed as previously described, Wright's Giemsa dye solution for 30 seconds, add distilled water dropwise to dye for 15 minutes. Wash the slides last, and microscopy was performed on Axio microscope using 100X/1.25 NA oil objective.
qRT-PCR and small interfering RNA transfection

Trizol reagent (Invitrogen, China) was used to separate total ribonucleic acid from cultured cells and used Prime-Script RT Master Mix (Takara) to obtain cDNA. At last, use TB Green Premix Ex Taq (Takara) to make realtime PCR. The TLN1 primer used for the amplification was as follows: 5′- AGTGACGGACAGCATCAACCAG-3′and 5′- GGATTCTCAGAGTCTCGGAG-3′ (Tongyong Biotech, China). Cells were transfected with siRNA using Lipofectamine 8000 (Beyotime Biotechnology, China). The targeting sequence of small interfering RNAs were siRNA1: 5′- GGU ACA GAA UCU AGA GAA ATT′ and siRNA2: 5′- GGA TTC TCC AGG AGT TCT CGGA-3′ (Tongyong Biotech, China). The targeting sequence of small interfering RNAs were siRNA1: 5′- GGUACGAAUCAGAGAAATT′ and 5′- UUUCUCAGAUUCUGUACCTT′, siRNA2: 5′- UGUAUAUUCCUCUUUUCUC′ and 5′- GAA AAAGGAGAAAUAACAGG′ (Tongyong Biotech, China).

Western blotting

After using siRNA transfection 48 h, the cells in each group were lysed with RIPA lystate and centrifuged for half an hour (4 °C, 13000 r/min). Other western blotting steps are the same as previous studies[16]. Caspase-3 antibody was purchased from Cell Signalling Technology (Beverly, MA, USA). Phosphorylated-AKT, CREB, Talin1 and PARP were purchased from Proteintech Technology (Beverly, MA, USA). Phosphorylated-AKT, CREB, Talin1 and PARP were purchased from Proteintech Technology (Wuhan, China). Total AKT was purchased from Zen-bioscience (Chengdu, China). This procedure was repeated 3 times for each protein sample.

Co-immunoprecipitation analysis

Collect the cells in logarithmic growth phase, add an appropriate amount of fine RIPA lysis buffer (containing protease inhibitors), and lyse on ice for 30 min. Take 100uL of lystate for Western blot analysis, add 1μg of the corresponding antibody to the remaining lysate, and incubate overnight at 4 °C with slow shaking. Take 10 ul protein A agarose beads, wash 3 times with an appropriate amount of lysis buffer, and centrifuge at 3000 rpm for 3 min each time. Add 10 ul of pretreated protein A agarose beads to the cell lysate incubated with the antibody overnight at 4 °C and incubate with slow shaking for 2-4 h to couple the antibody to the protein A agarose beads. After immunoprecipitation, centrifuge at 3000 rpm for 3 min at 4 °C, centrifuge the agarose beads to the bottom of the tube and remove the supernatant. Wash the agarose beads 3-4 times with 1 ml lysis buffer, and add SDS loading buffer, boiled for 5 minutes, use Western blotting for analysis.

Cell cycle analysis

The cells were treated with siRNA transfection for 48 hours and fixed overnight with 70% ethanol at −4 °C. After two times of PBS cleaning, PI staining was used for 30 minutes on the flow cytometer for testing and the CytExpert software was used to analyze data.

Statistical analysis

Statistical obtained from TCGA and GTEX were analyzed by R-3.6.1. Other datas were processed using GraphPad Prism 8, Flowjo and CytExpert software. P < 0.05 was considered statistically significant.

Results

TCGA samples information and TLN1 expression analysis in pan-cancers and AML

The RNAseq data of the AML and the normal control samples are uniformly processed by the Toil process downloaded from UCSC XENA, and the RNAseq data in TPM (transcripts per million reads) format are analyzed and compared after log2 conversion. We found that TLN1 is abnormally highly expressed in 12 tumors including AML, compared with normal tissues (Fig. 1A and B). Then we used The Human Protein Atlas (https://www.proteinatlas.org/) to analyze the expression level of TLN1 in human blood cells, found that the RNA expression of TLN1 showed low cell-type specificity (Fig. 1C). Finally, we used UCSC XENA to analyze the RNA expression, exon expression and DNA methylation of TLN1 in the TCGA AML cohort (Fig. 1D). We found that DNA methylation level was significantly increased at the probe of cg14025149 and cg14095761 (Fig. 1E).

The relationship between the expression of TLN1 and the prognosis and clinical characteristics of patients

We used survival package (3.2-10 version) for statistical analysis of survival data and survminer package [0.4.9 version] for visualization and drawing Kaplan-Meier survival curves. The high expression of TLN1 is related to poor overall survival (OS) in AML (Fig. 2A). In addition, higher TLN1 expression was significantly associated with poor prognosis in Brain Lower Grade Glioma, Adrenocortical carcinoma, Oral squamous Cell Carcinoma, Colon adenocarcinoma, Glioma, Cervical squamous cell carcinoma and endocervical adenocarcinoma, indicating that TLN1 was a potential oncogene in these types of cancers (Supplementary Fig. 1A-F). Since M3 patients generally represent a group with a better prognosis in the AML cohort, we redraw the survival curves after excluding M3. Results show that high expression of TLN1 still leads to poor OS (Supplementary Fig. 1G). ROC analysis for AML patients shows that TLN1 was a significant prognostic marker for OS. The Conformity Index (C-index) was 0.721 (95% Confidence interval:0.693-0.748) (Fig. 2B). The results of the multiple hypothesis test (Dunn's test) show...
**Fig. 1** TLN1 expression in pan-cancer.  
A TLN1 expression in tumor and normal tissues in pan-cancer data of The Cancer Genome Atlas (TCGA) and GTEx.  
B TLN1 expression in tumor and normal tissues in AML.  
C RNA expression of TLN1 in blood cells.  
D Heatmap showing the correlations between TLN1 methylation, exon expression and mRNA expression in AML via UCSC Xena.  
E Analysis of methylation probe of TLN1 in AML. Data were shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (ACC: Adrenocortical carcinoma; BLCA: Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangio carcinoma; COAD: Colon adenocarcinoma; DLBCL: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and Neck squamous cell carcinoma; KICH: Kidney Chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LAML: Acute Myeloid Leukemia; LGG: Brain Lower Grade Glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OVCAR: Ovarian serous cystadenocarcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Phaeochromocytoma and Paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SARC: Sarcoma; SKCM: Skin Cutaneous Melanoma; STAD: Stomach adenocarcinoma; TGCT: Testicular Germ Cell Tumors; THCA: Thyroid carcinoma; THYM: Thymoma; UCEC: Uterine Corpus Endometrial Carcinoma; UCS: Uterine Carcinosarcoma; UVM: Uveal Melanoma.)
that the groups of intermediate and poor are higher than the average of Favorable, the difference is statistically significant ($P < 0.05$) (Fig. 2C). Mann-Whitney U test (Wilcoxon rank-sum test) results show that the expression level of $\text{TLN1}$ increased significantly when the age > 60, the median of the difference between the

---

**Fig. 2** Correlation between $\text{TLN1}$ expression and clinical characteristics or prognosis. A High expression of $\text{TLN1}$ is associated with poor prognosis of AML. B ROC analysis of $\text{TLN1}$ in the prognosis of AML. C Correlation between $\text{TLN1}$ and cytogenetic risk. D Correlation between $\text{TLN1}$ and age. E Correlation between $\text{TLN1}$ and FAB classification. F Correlation between $\text{TLN1}$ and OS event. G Univariate and multivariate cox analysis of $\text{TLN1}$ in AML. H The nomogram of age (> 60 years), Cytogenetic risk, $\text{TLN1}$ and FLT3 mutation in the prognosis of AML.
two groups is 0.327 (0.08-0.545), the difference is statistically significant ($P=0.009$) (Fig. 2D). The original FAB classification of AML shows that the expression level of $TLN1$ is higher in M5, M6 and M7 than in M3 (Fig. 2E). Similarly, the expression of $TLN1$ was also related to the higher frequency dead of OS events (Fig. 2F). Next, we downloaded the clinical characteristics of TCGA patients and divided them into high expression groups and low expression groups according to the median of TPM (Table 1). We used univariate and multivariate Cox regression analysis to evaluate prognostic variables related to OS. The univariate Cox model showed that high $TLN1$ expression is closely related to poor OS (HR = 1.968 (95% Confidence interval: 1.287 – 3.187)). In addition, age (>60 years), Cytogenetic risk (intermediate and poor) were also poor prognostic factors for AML patients. The multivariate Cox model showed that age (>60 years), Cytogenetic risk (intermediate and poor), FLT3 mutation and $TLN1$ were independent poor prognostic factors for AML patients (Fig. 2G). Therefore, we used the nomogram to show the correlation between $TLN1$ expression and prognosis (Fig. 2H).

**TLN1** related gene enrichment analysis

To investigate genes related to $TLN1$, we used LinkeDomics to analyze co-expressed genes of $TLN1$ in AML [13]. After screening with $P<0.05$ and |correlation coefficient| >0.5, we got 285 genes revealed a significant positive association with $TLN1$, while 165 genes indicated significantly negative associations (Fig. 3A-C). Then we used 450 genes related to $TLN1$ for GO|KEGG and GSEA enrichment analysis. GO enrichment analysis results showed that $TLN1$ may be involved in neutrophil mediated immunity, neutrophil activation and neutrophil degranulation etc. (Fig. 3D and E). Annotations of pathway functions for enrichment analysis can be found in Supplementary table 1. We also analyzed the chord chart for several main enrichment functions, the enrichment function notes are shown in Fig. 3F. In addition, GSEA enrichment analysis results show that $TLN1$ may be related to multiple signaling pathways in hematological tumors, including tyrosine kinase receptor, PI3K/AKT/mTOR and FLT3 signaling pathway (Fig. 4A-K). Next, the analysis of cancer pathway activity showed that $TLN1$ may participate in the activation of EMT, PI3K/AKT, RAS/MAPK and RTK pathways (Fig. 4L). Complementary, drug sensitivity analysis showed $TLN1$ may be related to the resistance of PD-153035, austocystin-D and Afatinib. (5Z)-7-Oxozaenol, AZD6482 and BX-795 may provide a therapeutic strategy for targeting $TLN1$ (Fig. 4M and N).

### Table 1 TCGA AML patient characteristics and $TLN1$ expression correlated with clinical characteristics

| Characteristic | Low expression of $TLN1$ | High expression of $TLN1$ | $p$ | Statistic |
|---------------|--------------------------|--------------------------|-----|-----------|
| N             | 75                       | 76                       | 0.061 | 3.51 |
| Gender, n (%) |                          |                          | 0.061 | 3.51 |
| Female        | 40 (26.5%)               | 28 (18.5%)               |      |           |
| Male          | 35 (23.2%)               | 48 (31.8%)               |      |           |
| Race, n (%)   |                          |                          | 0.887 |           |
| Asian         | 0 (0%)                   | 1 (0.7%)                 |      |           |
| Black or African American |           | 7 (4.7%)               | 6 (4%) |           |
| White         | 66 (44.3%)               | 69 (46.3%)               |      |           |
| Age, n (%)    |                          |                          | 0.025* | 5.03 |
| < =60         | 51 (33.8%)               | 37 (24.5%)               |      |           |
| > 60          | 24 (15.9%)               | 39 (25.8%)               |      |           |
| WBC count(x 10^9/L), n (%) |      |                          | 0.417 | 0.66 |
| < =20         | 35 (23.3%)               | 42 (28%)                 |      |           |
| > 20          | 39 (26%)                 | 34 (22.7%)               |      |           |
| BM blasts(%), n (%) |          |                          | 0.444 | 0.59 |
| < =20         | 27 (17.9%)               | 33 (21.9%)               |      |           |
| > 20          | 48 (31.8%)               | 43 (28.5%)               |      |           |
| PB blasts(%), n (%) |          |                          | 0.932 | 0.01 |
| < =70         | 35 (23.2%)               | 37 (24.5%)               |      |           |
| > 70          | 40 (26.5%)               | 39 (25.8%)               |      |           |
| Cytogenetic risk, n (%) |      |                          | 0.077 | 5.12 |
| Favorable     | 21 (14.1%)               | 10 (6.7%)                |      |           |
| Intermediate  | 37 (24.8%)               | 45 (30.2%)               |      |           |
| Poor          | 16 (10.7%)               | 20 (13.4%)               |      |           |
| FAB classifications, n (%) |      |                          | 0.121 | 11.42 |
| M0            | 9 (6%)                   | 6 (4%)                   |      |           |
| M1            | 17 (11.3%)               | 18 (12%)                 |      |           |
| M2            | 21 (14%)                 | 17 (11.3%)               |      |           |
| M3            | 11 (7.3%)                | 4 (2.7%)                 |      |           |
| M4            | 12 (8%)                  | 17 (11.3%)               |      |           |
| M5            | 4 (2.7%)                 | 11 (7.3%)                |      |           |
| M6            | 0 (0%)                   | 2 (1.3%)                 |      |           |
| M7            | 0 (0%)                   | 1 (0.7%)                 |      |           |
| Cytogenetics, n (%) |          |                          | 0.237 | 10.41 |
| Normal        | 32 (23.7%)               | 37 (27.4%)               |      |           |
| +8            | 4 (3%)                   | 4 (3%)                   |      |           |
| del(5)        | 1 (0.7%)                 | 0 (0%)                   |      |           |
| del(7)        | 1 (0.7%)                 | 5 (3.7%)                 |      |           |
| inv(16)       | 5 (3.7%)                 | 3 (2.2%)                 |      |           |
| t(15;17)      | 7 (5.2%)                 | 4 (3%)                   |      |           |
| t(8;21)       | 6 (4.4%)                 | 1 (0.7%)                 |      |           |
| t(9;11)       | 0 (0%)                   | 1 (0.7%)                 |      |           |
| Complex       | 14 (10.4%)               | 10 (7.4%)                |      |           |
| FLT3 mutation, n (%) |      |                          | 0.846 | 0.04 |
| Negative      | 51 (34.7%)               | 51 (34.7%)               |      |           |
| Positive      | 24 (16.3%)               | 21 (14.3%)               |      |           |
Expression of TLNI in AML samples and cell lines
To further investigate the expression of TLNI in AML, we verified the expression level of TLNI in AML cell lines using qRT-PCR and Western blot (Fig. 6A and B). The result showed that the mRNA and protein expression levels of Talin1 were the highest in the acute monocytic leukemia cell line (THP-1). Next, we verified the protein expression level of Talin1 in the mononuclear cells of normal people and AML patients. The result showed that Talin1 expression was low or undetectable in normal people, and the expression level is abnormally increased in most AML patients (Fig. 6C and D). In addition, we used immunofluorescence staining to observe the localization of Talin1 in AML cell lines and the results showed that Talin1 is mainly located in the cell membrane and cytoplasm (Fig. 6E).

Interaction of Talin1 with MYH9
In previous bioinformatics analysis, we found an extraordinary association between TLNI and MYH9. We speculate that Talin1 and MYH9 may bind and interact with each other. We performed co-immunoprecipitation to confirm our speculation, and MYH9 was precipitated by Talin1-tagged agarose beads in HL60 and THP-1 (Fig. 6F). The result of Western blot shows that silencing TLNI also reduces MYH9 expression (Fig. 6G). Furthermore, we observed the intracellular distribution of Talin1 and MYH9 in HL60 and THP-1 by confocal laser microscopy, which indicated that Talin1 co-localized with MYH9 (Fig. 6H).

Silenced TLNI can inhibit the proliferation of AML cells and promote differentiation
After transfecting THP-1 and HL60 cell lines with small interfering RNA (siRNA), the expression level of TLNI was detected by qRT-PCR. As shown in Fig. 7A, both siRNA1 and siRNA2 could significantly reduce the expression level of Talin1 in the acute monocytic leukemia cell line (THP-1). Next, we verified the expression level of TLNI in AML samples and cell lines using qRT-PCR and Western blot (Fig. 6A and B). The result showed that the mRNA and protein expression levels of Talin1 were the highest in the acute monocytic leukemia cell line (THP-1). Next, we verified the protein expression level of Talin1 in the mononuclear cells of normal people and AML patients. The result showed that Talin1 expression was low or undetectable in normal people, and the expression level is abnormally increased in most AML patients (Fig. 6C and D). In addition, we used immunofluorescence staining to observe the localization of Talin1 in AML cell lines and the results showed that Talin1 is mainly located in the cell membrane and cytoplasm (Fig. 6E).

Table 1 (continued)

| Characteristic | Low expression of TLN1 | High expression of TLN1 | p       | Statistic |
|----------------|------------------------|-------------------------|---------|-----------|
| IDH1 R132 mutation, n (%) | 0.235 | 1.41 |
| Negative | 65 (43.6%) | 71 (47.7%) |
| Positive | 9 (6%) | 4 (2.7%) |
| IDH1 R140 mutation, n (%) | 0.745 | 0.11 |
| Negative | 70 (47%) | 67 (45%) |
| Positive | 5 (3.4%) | 7 (4.7%) |
| IDH1 R172 mutation, n (%) | 0.245 |
| Negative | 75 (50.3%) | 72 (48.3%) |
| Positive | 0 (0%) | 2 (1.3%) |
| RAS mutation, n (%) | 0.719 |
| Negative | 70 (46.7%) | 72 (48%) |
| Positive | 5 (3.3%) | 3 (2%) |
| NPM1 mutation, n (%) | 1.000 | 0 |
| Negative | 58 (38.7%) | 59 (39.3%) |
| Positive | 17 (11.3%) | 16 (10.7%) |
| OS event, n (%) | 0.112 | 2.52 |
| Alive | 32 (21.2%) | 22 (14.6%) |
| Dead | 43 (28.5%) | 54 (35.8%) |

Data were shown as mean±SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

PPI and immune infiltration analysis of TLNI
In the previous correlation analysis, MYH9 and FLNA showed a very significant correlation, and the correlation coefficients were 0.76 (p < 0.001) and 0.71 (p < 0.001). Therefore, we analyzed the expression and prognosis of MYH9 and FLNA in the TCGA AML cohort. The results showed that MYH9 was abnormally highly expressed in AML patients and both of MYH9 and FLNA were associated with poor prognosis (Fig. 5A). Using GeneMANIA to predict TLNI and MYH9-related PPI network results showed that the functions were concentrated in blood coagulation, cell-cell junction organization, coagulation, hemostasis, homotypic cell-cell adhesion, platelet activation (Fig. 5B). We co-expression analysis of the top 15 gens with the highest scores in the PPI network (Fig. 5C), and the expression of PIPS5KC, ROCK1, S100A4, MY01A and WAC is abnormally increased in AML (Fig. 5D-H). This showed that TLNI may work together with PIPS5KC, ROCK1, S100A4, MY01A and WAC in AML. The results of immune infiltration analysis of TLNI using R showed that TLNI expression was significant associations with multiple immune cells including macrophages (p < 0.001, r = 0.428), Tem (p < 0.001, r = 0.426), iDC (p < 0.001, r = 0.421) etc. (Fig. 5I). This means that TLNI may be an important marker of immune infiltration in AML.

TLNI expression was significantly associated with immune cells including macrophages (p < 0.001, r = 0.428), Tem (p < 0.001, r = 0.426), iDC (p < 0.001, r = 0.421) etc. (Fig. 5I). This means that TLNI may be an important marker of immune infiltration in AML.

Expression of TLNI in AML samples and cell lines
To further investigate the expression of TLNI in AML, we verified the expression level of TLNI in AML cell lines using qRT-PCR and Western blot (Fig. 6A and B). The result showed that the mRNA and protein expression levels of Talin1 were the highest in the acute monocytic leukemia cell line (THP-1). Next, we verified the protein expression level of Talin1 in the mononuclear cells of normal people and AML patients. The result showed that Talin1 expression was low or undetectable in normal people, and the expression level is abnormally increased in most AML patients (Fig. 6C and D). In addition, we used immunofluorescence staining to observe the localization of Talin1 in AML cell lines and the results showed that Talin1 is mainly located in the cell membrane and cytoplasm (Fig. 6E).

Interaction of Talin1 with MYH9
In previous bioinformatics analysis, we found an extraordinary association between TLNI and MYH9. We speculate that Talin1 and MYH9 may bind and interact with each other. We performed co-immunoprecipitation to confirm our speculation, and MYH9 was precipitated by Talin1-tagged agarose beads in HL60 and THP-1 (Fig. 6F). The result of Western blot shows that silencing TLNI also reduces MYH9 expression (Fig. 6G). Furthermore, we observed the intracellular distribution of Talin1 and MYH9 in HL60 and THP-1 by confocal laser microscopy, which indicated that Talin1 co-localized with MYH9 (Fig. 6H).

Silenced TLNI can inhibit the proliferation of AML cells and promote differentiation
After transfecting THP-1 and HL60 cell lines with small interfering RNA (siRNA), the expression level of TLNI was detected by qRT-PCR. As shown in Fig. 7A, both siRNA1 and siRNA2 could significantly reduce the expression level of Talin1 in the acute monocytic leukemia cell line (THP-1). Next, we verified the expression level of TLNI in AML samples and cell lines using qRT-PCR and Western blot (Fig. 6A and B). The result showed that the mRNA and protein expression levels of Talin1 were the highest in the acute monocytic leukemia cell line (THP-1). Next, we verified the protein expression level of Talin1 in the mononuclear cells of normal people and AML patients. The result showed that Talin1 expression was low or undetectable in normal people, and the expression level is abnormally increased in most AML patients (Fig. 6C and D). In addition, we used immunofluorescence staining to observe the localization of Talin1 in AML cell lines and the results showed that Talin1 is mainly located in the cell membrane and cytoplasm (Fig. 6E).

Silenced TLNI can inhibit the proliferation of AML cells and promote differentiation
After transfecting THP-1 and HL60 cell lines with small interfering RNA (siRNA), the expression level of TLNI was detected by qRT-PCR. As shown in Fig. 7A, both siRNA1 and siRNA2 could significantly reduce the expression level of Talin1 in the acute monocytic leukemia cell line (THP-1). Next, we verified the expression level of TLNI in AML samples and cell lines using qRT-PCR and Western blot (Fig. 6A and B). The result showed that the mRNA and protein expression levels of Talin1 were the highest in the acute monocytic leukemia cell line (THP-1). Next, we verified the protein expression level of Talin1 in the mononuclear cells of normal people and AML patients. The result showed that Talin1 expression was low or undetectable in normal people, and the expression level is abnormally increased in most AML patients (Fig. 6C and D). In addition, we used immunofluorescence staining to observe the localization of Talin1 in AML cell lines and the results showed that Talin1 is mainly located in the cell membrane and cytoplasm (Fig. 6E).
showed that silenced *TLN1* significantly reduced the proliferation ability of AML cells (Fig. 7E). We also tested the expression level of apoptosis protein silenced by *TLN1*, as shown in Fig. 7F, the expression of Caspase3 in *TLN1* silenced group cells was significantly increased, but PARP did not change significantly. This means that the silencing of *TLN1* may lead to apoptosis of AML cells. In summary, these results indicate that *TLN1* participates in the progression of AML by regulating the proliferation, apoptosis, differentiation and cell cycle of AML cells.
**TLN1 regulates the proliferation and differentiation of AML cells by Talin1/p-AKT/CREB signaling pathway**

According to the enrichment analysis result of GSEA, *TLN1* may be related to the PI3K/AKT signaling pathway. Therefore, we tested the expression levels of AKT and P-AKT after *TLN1* silence. Our results showed that interfering with the expression of Talin1 reduced the expression level of P-AKT. Similarly, the expression level of CREB was also downregulated which was a signal molecule downstream of AKT and related to cell proliferation and differentiation (Fig. 7G). These results indicated that *TLN1* may regulate the proliferation and differentiation of AML cells by regulating the expression of Talin1/p-AKT/CREB.

**Discussion**

The protein Talin1 encoded by *TLN1* is a focal adhesion cytoskeleton protein that binds and activates integrins, and integrins recruit other focal adhesion kinases (FAKs). Studies have shown that Talin is an indispensable factor for endothelial cell-mediated angiogenesis [14]. In patients with multiple myeloma and chronic lymphocytic leukemia, Talin1 can also promote the abnormal transport of malignant B cells to the bone marrow and lymph nodes by regulating α4β1 integrin activity. The abnormal homing of these malignant cells to the bone marrow microenvironment can induce cell adhesion-mediated drug resistance [15]. In addition, Arundhati Halder et al. analyzed one publicly available chronic myeloid leukemia (CML) RNA-sequencing dataset (SRA073794) found that Talin1 (*TLN1*) was upregulated by 6 times in CML-blast crisis (BC) compared with the CML-chronic phase (CP) stage [16]. These results imply that *TLN1* may play an important role in hematopoietic malignancies.

In this study, we used a variety of bioinformatics analysis and functional analysis methods to explore the expression, prognostic role and biological function of *TLN1* in AML. Our results show that the RNA and protein of Talin1 (*TLN1*) are abnormally highly expressed in AML samples, which may be a prognostic marker of AML patients. Unfortunately, we were unable to analyze the role of *TLN1* in event free survival, relapse and disease progression due to the limited clinical information provided by the TCGA data. However, enrichment analysis results show that *TLN1* is related to multiple functions of neutrophils and may be involved in multiple important signal pathways in hematopoietic malignancies.

Non-muscle myosin heavy chain9 (*MYH9*) is widely expressed in various tissues and cells. *MYH9* is abnormally highly expressed in esophageal squamous cell carcinoma [17], breast cancer [18], epithelial ovarian cancer [19] and acute myeloid leukemia [20] and is associated with poor prognosis. Researchers report that *MYH9* degrades GSK3β protein through TRAF6-induced ubiquitination, enhancing the stem cell characteristics, migration, invasion, growth and sorafenib resistance of HCC cells [21]. This means that *MYH9* may be a promising target gene for cancer treatment. Our analysis found that *TLN1* strongly correlates with *MYH9*, and *TLN1* may work with *MYH9*, PIP5K1C, ROCK1, S100A4, MY01A and WAC to promote the growth and invasion of AML cells. Co-immunoprecipitation and immunofluorescence experiments confirmed the interaction between *TLN1* and *MYH9*. However, the mechanism of action between *TLN1* and *MYH9* needs more experiments to verify.

The transcription factor CREB (cAMP response element binding protein) is a nuclear protein that selectively binds to the cyclic adenylate response element to regulate cell proliferation, differentiation and apoptosis [22]. Research has shown that the expression level of CREB in acute leukemia cells is significantly higher than that of normal bone marrow cells, and the high expression of CREB is associated with a poor prognosis [23]. In addition, CREB can be used as a proto-oncogene to be activated through the AKT signaling pathway, which can regulate cell production in the blood and affect the phenotype of leukaemia [24]. Our study found that interference with the expression of *TLN1* can reduce the level of CREB by down-regulating the expression of P-AKT. Therefore, the Talin1/P-AKT/CREB signal pathway regulated by *TLN1* may become a new therapeutic target for AML.

The 13 rod-shaped of Talin1 (R1-R13) domains are entangled into a compact globular structure [25, 26], and the R4 domain is buried in the core to protect R4 from being combined with other proteins to function [27]. The conformational changes of Talin1 can be regarded as a collection of open and closed states, which can be reversibly changed by changes in the microenvironment in the body. This autoinhibition...
Fig. 4 (See legend on previous page.)
Fig. 5  PPI network and analysis of immune infiltration. A The expression and prognosis of MYH9 and FLNA in AML. B PPI network of TLN1 and MYH9 using GeneMANIA. C Heat map of co-expressed genes of TLN1 and MYH9. PIP5K1C, ROCK1, S100A4, MY01A and WAC expression in tumor and normal tissues in AML (D-H). I: Correlation between expression of TLN1 and immune infiltration
mode can appropriately turn off the adhesion components to control cell attachment and migration [28]. We speculate that this autoinhibition state may change in AML patients, resulting in abnormally abnormal activation of Talin1, thereby promoting the proliferation of AML cells. In conclusion, TLN1 is a potential prognostic and therapeutic biomarker of AML, and it can affect the immune microenvironment to promote

Fig. 6 Expression of TLN1 in cell lines and samples. A Protein expression level of TLN1 in AML cell lines. B RNA expression level of TLN1 in AML cell lines. C The protein expression level of TLN1 in normal people. D The protein expression level of TLN1 in AML patients. E Immunofluorescence staining of TLN1 in THP-1 and HL60. F Co-immunoprecipitated MYH9 was detected using MYH9 antibody. G MYH9 expression is reduced after silencing of TLN1. H The co-localization between Talin1 (green) with MYH9 (red) was analyzed by confocal microscopy in HL60 and THP-1.
Fig. 7 RNA interference and pathway analysis of TLN1. A HL60 and THP-1 cells were transfected with siRNA, the level of TLN1 was evaluated by qRT-PCR. B Wright–Giemsa staining of control and TLN1-silenced cells. The flow cytometric analysis was carried out to analysis the cell cycle distribution (C–D). E The proliferation of THP-1 and HL60 was examined by cell counts. F The expression levels of apoptosis-related proteins were evaluated by Western blot in control and TLN1-silenced cells. G The expression levels of Talin1/p-AKT/CREB proteins were evaluated by Western blot in control and TLN1-silenced cells. Data were shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
the proliferation of AML cells and inhibit differentiation and regulate multiple signal pathways in hematologic malignancies. However, the regulatory effect of TLN1 on the immune microenvironment and the interaction between TLN1 and MYH9 need to be further confirmed by experimental data.

Abbreviations
AML: Acute myeloid leukemia; TPM: Transcripts per million reads; CREB: cAMP response element binding protein; PPI: Protein-protein interaction; GSEA: Gene Set Enrichment Analysis; GSCA: Gene Set Cancer Analysis; TCGA: The cancer genome atlas; GTEx: Genotype-Tissue Expression; OS: Overall survival; MYH9: Non-muscle myosin heavy chain9.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-10099-0.

Additional file 1: Supplementary Figure1. High expression of TLN1 is associated with poor prognosis of Brain Lower Grade Glioma (A), Adenocortical carcinoma (B), Oral squamous Cell Carcinoma (C), Colorectal adenocarcinoma, Glioma (D), Cervical squamous cell carcinoma (E) and endocervical adenocarcinoma (F). G: Kaplan–Meier survival curves for TLN1 in AML cohort after excluding M3 patients.

Additional file 2: Supplementary Table 1. The gene function notes of GO and KEGG enrichment analysis.

Additional file 3.
Additional file 4.
Additional file 5.
Additional file 6.

Acknowledgements
Not applicable.

Authors’ contributions
Di Cui and Xilong Cui wrote the main manuscript text and Wenjing Zhang and Weizhen Zhang prepared Figs. 1, 2 and 3. Yingxin Gao and Yu Yu prepared Figs. 4 and 5. Chuanzhong Mei prepared Figs. 6 and 7. Xiaoliang Xu completed some supplementary experiments. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding
This study was supported by the National Natural Scientific Foundation of China (No. 81702154), China Postdoctoral Science Foundation (2019M62209), Research Fund for Postdoctoral Researchers of Anhui Province (2019B380), Quality Engineering Project of Anhui Education Department (2017jxyxm106,2020kckfcs586), Quality Engineering Project of University of Science and Technology of China (No.2020xyxm112), Key Natural Science Project of Bengbu Medical College (No. 2020byzd026), Bengbu Medical College Graduate Research and Innovation Project (No. Byycxx202020).

Availability of data and materials
All analyzed data are included in this published article and its supplementary information file. The data underlying this study are freely available from UCSC XENA (https://xenabrowser.net/datapages/). The authors did not have special access privileges. All data included in this study are available upon request by contact with the corresponding author.

Declarations

Ethics approval and consent to participate
This study was conducted under the approval of the Ethics Committee of the First Affiliated Hospital of University of Science and Technology of China. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the Ethics Committee. All patients and/or legal guardians were informed prior to experiments and signed written informed consents.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing financial interests.

Author details
1 Medical College, Fuyang Normal University, Fuyang 236037, Anhui, China. 2 Spinal Deformity Clinical Medicine and Research Center of Anhui Province, 501 Sanqing Road, Fuyang 236000, Anhui, China. 3 School of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, Anhui, China. 4 Division of Life Sciences and Medicine, Department of Clinical Laboratory, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei 230001, Anhui, China.

Received: 1 March 2022 Accepted: 13 September 2022
Published online: 29 September 2022

References
1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.
2. Siegel RL, Miller KD. Jemal a, Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
3. Jung L, Cho BS, Kim HJ, et al. Reclassification of acute myeloid leukemia according to the 2016 WHO classification. Ann Lab Med. 2019;39(3):311–6.
4. Ferrara F, Schiffer C a, acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484–95.
5. Vachon PH. Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J Signal Transduction. 2011;2011:738137.
6. Wegener KL, Partridge AW, Han J, et al. Structural basis of integrin activation by Talin. Cell. 2007;128(1):171–82.
7. Goult BT, Yan J, Schwartz M a, Talin as a mechanosensitive signaling hub. J Cell Biol. 2018;217(11):3776–84.
8. Singel SM, Cornelius C, Batten K, et al. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(8):2061–70.
9. Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–6.
10. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
11. Yu G, Wang LG, Han Y, et al. ClusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–7.
12. Warde-Farley D,Donaldson S L,Comes O, et al, The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010;38 (Web Server issue), W214-20.
13. Vasakar SV,Straub P,Wang J,et al.LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–d963.
14. Lim IR, Joo HJ, Jeong M, et al. Talin modulation by a synthetic N-Acylurea derivative reduces angiogenesis in human endothelial cells. Int J Mol Sci. 2017;18(1):221.
15. Martínez-Moreno M, Leiva M, Aguiller-Montilla N, et al. In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by o461 cytoplasmic-binding proteins. Leukemia. 2016;30(4):861–72.
16. Halder A, Nayak KB. Chakraborty S, Ecotopic viral infection site 1 (EV11) transcriptionally targets talin1 (TLN1) and upregulates its expression in chronic myeloid leukemia. Leukemia Lymphoma. 2018;59(8):2008–10.
17. Yang B, Liu H, Bi Y, et al. MYH9 promotes cell metastasis via inducing angiogenesis and epithelial Mesenchymal transition in esophageal squamous cell carcinoma. Int J Med Sci. 2020;17(13):2013–23.
18. Betapudi VL, Li D, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res. 2006;66(9):4725–4733.

19. Liu L, Yi J, Deng X, et al. MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer. Oncol Lett. 2019;18(2):1049–56.

20. Yu M, Wang J, Zhu Z, et al. Prognostic impact of MYH9 expression on patients with acute myeloid leukemia. Oncotarget. 2017;8(1):156–63.

21. Lin X, Li AM, Li YH, et al. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduction Targeted Therapy. 2020;5(1):13.

22. Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res. 2009;15(8):2583–7.

23. Shankar DB, Cheng JC, Sakamoto KM. Role of cyclic AMP response element binding protein in human leukemias. Cancer. 2005;104(9):1819–24.

24. Stepulak A, Sifringer M, Rzeski W, et al. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A. 2005;102(43):15605–10.

25. Calderwood DA, Campbell ID, Critchley DR. Talins and kindlins: partners in integrin-mediated adhesion. Nat Rev Mol Cell Biol. 2013;14(8):503–17.

26. Goult BT, Xu XP, Gingras AR, et al. Structural studies on full-length talin1 reveal a compact auto-inhibited dimer: implications for Talin activation. J Struct Biol. 2013;184(1):21–32.

27. Dedden D, Schumacher S, Kelley CF, et al. The architecture of Talin1 reveals an autoinhibition mechanism. Cell. 2019;179(1):120–131.e13.

28. Ellis SJ, Goult BT, Fairchild MJ, et al. Talin autoinhibition is required for morphogenesis. Curr Biol. 2013;23(18):1825–33.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.